WO2013128379A3 - Formes polymorphes cristallines de linagliptine - Google Patents

Formes polymorphes cristallines de linagliptine Download PDF

Info

Publication number
WO2013128379A3
WO2013128379A3 PCT/IB2013/051556 IB2013051556W WO2013128379A3 WO 2013128379 A3 WO2013128379 A3 WO 2013128379A3 IB 2013051556 W IB2013051556 W IB 2013051556W WO 2013128379 A3 WO2013128379 A3 WO 2013128379A3
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
polymorphic forms
crystalline polymorphic
polymorphs
crystalline
Prior art date
Application number
PCT/IB2013/051556
Other languages
English (en)
Other versions
WO2013128379A2 (fr
Inventor
Srividya Ramakrishnan
Subbareddy Peddireddy
Lalita Kanwar
Original Assignee
Dr. Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited
Publication of WO2013128379A2 publication Critical patent/WO2013128379A2/fr
Publication of WO2013128379A3 publication Critical patent/WO2013128379A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La présente demande concerne des polymorphes cristallins de linagliptine et des procédés pour les préparer. En outre, la présente demande concerne l'utilisation des nouveaux polymorphes de linagliptine pour la préparation d'un médicament, et des compositions pharmaceutiques comprenant une quantité efficace des polymorphes cristallins de linagliptine.
PCT/IB2013/051556 2012-02-27 2013-02-27 Formes polymorphes cristallines de linagliptine WO2013128379A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN723/CHE/2012 2012-02-27
IN723CH2012 2012-02-27
IN3401CH2012 2012-08-17
IN3401/CHE/2012 2012-08-17
IN5356/CHE/2012 2012-12-21
IN5356CH2012 2012-12-21

Publications (2)

Publication Number Publication Date
WO2013128379A2 WO2013128379A2 (fr) 2013-09-06
WO2013128379A3 true WO2013128379A3 (fr) 2013-10-31

Family

ID=49083398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/051556 WO2013128379A2 (fr) 2012-02-27 2013-02-27 Formes polymorphes cristallines de linagliptine

Country Status (1)

Country Link
WO (1) WO2013128379A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102442536B1 (ko) * 2015-09-17 2022-09-13 한미정밀화학주식회사 리나글립틴 결정형 및 이의 제조방법
CN109748919A (zh) * 2017-11-07 2019-05-14 四川科伦药物研究院有限公司 一种利格列汀的晶型及其制备方法
TR201720515A2 (tr) 2017-12-15 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Li̇nagli̇pti̇n i̇çeren bi̇r kati oral dozaj formu
CN109111443A (zh) * 2018-08-28 2019-01-01 上海迪赛诺药业股份有限公司 Dpp-iv抑制剂类降糖药的新晶型及其制备方法
CN110305131B (zh) * 2019-07-03 2021-12-31 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法
WO2021250995A1 (fr) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 Morphologie cristalline de 1- [(4-méthyl-quinazoline-2-yl)méthyl]-3-méthyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-péperidine-1-yl)-xanthine
CN113754664B (zh) * 2021-09-23 2022-08-16 山东罗欣药业集团股份有限公司 一种利格列汀晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128721A1 (fr) * 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphes
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2007128721A1 (fr) * 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphes

Also Published As

Publication number Publication date
WO2013128379A2 (fr) 2013-09-06

Similar Documents

Publication Publication Date Title
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
EP2535339A4 (fr) Polymorphes du dasatinib, leurs procédés de préparation et leurs compositions pharmaceutiques
EP2702054A4 (fr) Nouveaux composés bisaminoquinoléines, compositions pharmaceutiques préparées à partir de ceux-ci et leur utilisation
EP2938616A4 (fr) Procédé de préparation de tofacitinib et d'intermédiaires
HU1000069D0 (en) New salts for the preparation of pharmaceutical composition
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
WO2014072961A3 (fr) Formes polymorphes du suvorexant
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012037562A3 (fr) Compositions pharmaceutiques et nutraceutiques d'acide abscisique
IL232577A (en) History of morpholinylbenzotriazine, their preparation and their pharmaceutical preparations
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
IL223872A (en) Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them
EP2742020A4 (fr) Dérivé de biguanide à substitution n1-amine cyclique-n5, procédés de préparation associés et composition pharmaceutique les comprenant
EP2697238A4 (fr) Formes solides de composés antirétroviraux, procédé de préparation correspondant et composition pharmaceutique de ces composés
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EP2924042A4 (fr) Composé bis- -carboline et procédé de préparation, composition pharmaceutique et utilisation associée
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
IL230219B (en) History of dihydropyrazole, their preparation and pharmaceutical preparations containing them
EP2759547A4 (fr) Groupe partant contenant des dérivés amino ou alkylamino d'acide succinique du composé de platine, son procédé de préparation et ses applications
WO2011095985A3 (fr) Sels de rasagiline et procédés de preparation de ces derniers
IL230907A0 (en) Salt and formations of a pyrazolopyrimidine compound, a medical composition that includes the above, and a preparation and use process for them
IL218764A (en) Crystalline lupilopinic acid and the process for its preparation, its uses, and its pharmaceutical preparations
EP2766369A4 (fr) Nouveaux sels de sitagliptine, leur procédé de préparation et compositions pharmaceutique les contenant

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13754427

Country of ref document: EP

Kind code of ref document: A2